A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA).

Trial Profile

A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2012

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Restenosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Mar 2012 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 06 Oct 2011 Actual end date (September 2009) added as reported by ClinicalTrials.gov.
    • 21 Oct 2009 Actual patient number (228) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top